Landmark GLP-1 pricing drops to $245/mo, Lilly's retatrutide aces Phase 3, and investigations expose peptide quality failures and safety risks.
10 stories · Covering research, clinical-trials, industry, regulatory
Today's peptide news is dominated by a wave of major investigative journalism and significant clinical/regulatory developments. The New Yorker published a deep-dive into the gray-market peptide injection craze, The Guardian revealed that a third of tested peptide products fail quality checks, and TikTok users on retatrutide are reporting "emotional flattening." On the business side, the administration announced a landmark GLP-1 pricing deal that could drop costs to $245/month, Eli Lilly posted strong Phase 3 retatrutide data, and the oral GLP-1 rivalry between Foundayo and oral Wegovy is heating up.
Physician-journalist Dhruv Khullar traces the peptide movement from CrossFit communities to mainstream wellness, documenting contamination (lead in BPC-157, endotoxins in TB-500), lack of human trials, and RFK Jr.'s attacks on FDA restrictions.
Retatrutide met its primary endpoint of superior A1C reduction and all key secondary endpoints at 40 weeks compared with placebo in type 2 diabetes patients, also demonstrating significant weight loss.
Injectable semaglutide and tirzepatide will drop to ~$350/month initially and $245/month within two years, down from current list prices of $1,000–$1,350/month.
Labs report about a third of peptide products fail basic quality checks as the underground market explodes. Texas-based Finnrick processes ~60,000 samples per year, up from a handful per month.
TikTok users on retatrutide report emotional blunting. Neuroscientist Paul Kenny of Mount Sinai says researchers are investigating whether GLP-1 drugs act as general reward dampeners affecting the brain's mesolimbic system.
MEDVi, a $1.8B AI-powered telehealth company with just two full-time employees, received an FDA warning letter in February 2026 for misbranding compounded semaglutide and tirzepatide.
The ACHIEVE-3 trial in The Lancet showed Eli Lilly's Foundayo (orforglipron) superior on HbA1c, while Novo Nordisk's oral Wegovy may have an edge in weight-loss efficacy.
The UK's medicines regulator is investigating whether clinics are breaking the law by making unsubstantiated medicinal claims for unregulated peptide therapies.
Wall Street bets GLP-1 drugs will transform food. Packaged-food giants are down 50%+ from peaks. Goldman projects these drugs could add over 1% to GDP if adoption reaches 60 million Americans by 2028.
Beijing-based Syneron Bio raised $150M in Series B funding with AstraZeneca among investors to develop macrocyclic peptide drugs. The FDA also proposed a new expedited IND pathway.